Handle with care: targeting neutrophils in chronic obstructive pulmonary disease and severe asthma?
Neutrophils play an important role in the pathogenesis of airway inflammation in both chronic obstructive pulmonary disease (COPD) and severe asthma. Currently available drugs have only limited effects on neutrophilic airway inflammation, particularily in COPD. Therefore, great efforts are undertaken to address neutrophilic inflammation in chronic respiratory disorders, in particular COPD. This review summarizes the rationale for anti-neutrophilic treatment in COPD and asthma and gives a critical overview of current developments in drug therapy. Moreover, unanswered questions and limitations of clinical trial design and choice of outcome parameters for proof-of-concept studies with novel anti-neutrophilic drugs are discussed as well as potential safety issues.
Beeh
K M
KM
Insaf Respiratory Research Institute, Wiesbaden, Germany. k.beeh@insaf-wi.de
Beier
J
J
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D036904:Leukocyte Rolling / Q000187:drug effects; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D009504:Neutrophils / Q000187:drug effects*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000276:immunology
D000893:Anti-Inflammatory Agents; D004791:Enzyme Inhibitors; D020024:Leukotriene Antagonists